Skip to main content
Log in

Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil

  • Brief Report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract 

We report a 21-year-old male with childhood-onset familial nephrotic syndrome and frequent relapses who manifested toxicity or treatment resistance to corticosteroids, cyclophosphamide, cyclosporin-A, and tacrolimus. Monotherapy with mycophenolate mofetil (MMF) resulted in maintenance of clinical remission for 14 months without noticeable toxicity, while allowing resolution of steroid-induced side effects. Our observation suggests that MMF may be useful in maintaining remission in nephrotic patients who manifest toxicity to standard immunosuppressive agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 6 April 1999 / Revised: 10 August 1999 / Accepted: 13 August 1999

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chandra, M., Susin, M. & Abitbol, C. Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil. Pediatr Nephrol 14, 224–226 (2000). https://doi.org/10.1007/s004670050047

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s004670050047

Navigation